Format

Send to

Choose Destination
Spinal Cord. 2012 Nov;50(11):836-9. doi: 10.1038/sc.2012.62. Epub 2012 May 29.

The use of bronchodilators in people with recently acquired tetraplegia: a randomised cross-over trial.

Author information

1
Rehabilitation Studies Unit, Northern Clinical School, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.

Abstract

STUDY DESIGN:

A within-participant, double-blind, cross-over, randomised control trial.

OBJECTIVES:

To determine the short-term effects of bronchodilator therapy on respiratory function in people with recently acquired motor complete tetraplegia.

SETTING:

Hospital, Australia.

METHODS:

A total of 12 people with recently acquired tetraplegia were randomised to receive either a one-off dose of a bronchodilator followed by an equivalent dose of a placebo propellant between 1 day and 1 week later or visa versa. The three outcomes were forced expiratory volume in 1 s (FEV1), peak expiratory flow rate (PEF) and forced vital capacity (FVC). These were measured while supine by a blinded assessor 10 and 30 min after treatment. Data were analysed on 11 participants and reported as percentage of predicted.

RESULTS:

The FEV1, FVC and PEF mean between-group differences (95% confidence interval) at 10 min post treatment were 7.3% (2.7-11.9%; P=0.003), 5.5% (1.6-9.4%; P=0.008) and 20.1% (1.1-40.4%; P=0.039). Similar effects were observed at 30 min for FVC and FEV1 but not for PEF.

CONCLUSION:

Bronchodilator therapy has a beneficial effect on FEV1, FVC and PEF in participants with recently acquired tetraplegia.

PMID:
22641256
DOI:
10.1038/sc.2012.62
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center